Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LYEL

Lyell Immunopharma Inc

Jun 18 • 04:00PM ET

12.74

+0.22 1.76 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: EDIT BEAM NTLA BMRN CRSP INCY KRYS AXSM NBIX VSTM

| Held by: VTI VXF SCHA IBB VHT AVSC DFAS DFMC SCHB PRFZ

Index	-	P/E	-	EPS (ttm)	-12.74	Insider Own	66.69%	Shs Outstand	23.33M	Perf Week	-7.14%
Market Cap	297.28M	Forward P/E	-	EPS next Y	-7.99	Insider Trans	6.57%	Shs Float	7.77M	Perf Month	-21.02%
Enterprise Value	92.11M	PEG	-	EPS next Q	-2.03	Inst Own	18.91%	Short Float	17.42%	Perf Quarter	-38.66%
Income	-246.41M	P/S	9909.33	EPS this Y	52.16%	Inst Trans	0.56%	Short Ratio	14.65	Perf Half Y	-60.97%
Sales	0.03M	P/B	1.09	EPS next Y	-4.00%	ROA	-63.15%	Short Interest	1.35M	Perf YTD	-58.61%
Book/sh	11.73	P/C	1.17	EPS next 5Y	23.93%	ROE	-80.76%	52W High	45.00 -71.69%	Perf Year	32.99%
Cash/sh	10.89	P/FCF	-	EPS past 3/5Y	-2.70% 0.99%	ROIC	-78.69%	52W Low	8.46 50.59%	Perf 3Y	-80.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-92.48% -65.85%	Gross Margin	-33545.16%	Volatility	7.32% 8.72%	Perf 5Y	-96.07%
Dividend TTM	-	EV/Sales	3070.33	EPS Y/Y TTM	49.06%	Oper. Margin	-620790.32%	ATR (14)	1.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.23	Sales Y/Y TTM	-52.31%	Profit Margin	-794858.06%	RSI (14)	33.90	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	7.23	EPS Q/Q	68.79%	SMA20	-11.64%	Beta	-0.03	Target Price	37.17
Payout	-	Debt/Eq	0.18	Sales Q/Q	-71.43%	SMA50	-31.15%	Rel Volume	3.88	Prev Close	12.52
Employees	161	LT Debt/Eq	0.14	Earnings	May 06 AMC	SMA200	-38.65%	Avg Volume	92.37K	Price	12.74
IPO	Jun 17, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.14% -33.33%	Trades		Volume	358,655	Change	1.76%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Initiated	Robert W. Baird	Outperform	$49
Apr-10-26	Initiated	Needham	Buy	$44
Mar-09-26	Initiated	Citizens	Mkt Outperform	$34
Dec-09-25	Upgrade	H.C. Wainwright	Neutral → Buy	$45
Oct-30-24	Downgrade	BofA Securities	Buy → Underperform	$6 → $1
Jun-27-24	Downgrade	H.C. Wainwright	Buy → Neutral	$6 → $1
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral	$15 → $5
Nov-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$15 → $7
Nov-11-22	Downgrade	Goldman	Buy → Neutral	$13 → $7
Oct-17-22	Initiated	H.C. Wainwright	Buy	$12
Jul-12-21	Initiated	Morgan Stanley	Overweight	$25
Jul-12-21	Initiated	JP Morgan	Overweight	$22
Jul-12-21	Initiated	Goldman	Buy	$30
Jul-12-21	Initiated	BofA Securities	Buy	$25

Show Previous Ratings

Jun-12-26 12:45PM	Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress (GlobeNewswire)
Jun-08-26 06:00AM	Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion (GlobeNewswire)
Jun-04-26 04:05PM	Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress (GlobeNewswire) -8.28%
Jun-01-26 08:00AM	Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 (GlobeNewswire)
May-20-26 04:48PM	Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL) (Quartz) +6.76%
08:00AM	Loading…
May-12-26 08:00AM	Lyell Immunopharma Announces Participation in May Investor Conferences (GlobeNewswire)
May-06-26 05:17PM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 (GlobeNewswire)
Apr-07-26 08:00AM	Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-12-26 06:10PM	Lyell Immunopharma: Q4 Earnings Snapshot (Associated Press Finance) -14.23%
04:05PM	Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results (GlobeNewswire)
Mar-09-26 08:00AM	Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer (GlobeNewswire) +13.54%
Feb-23-26 08:00AM	Lyell Immunopharma Announces Participation in March Investor Conferences (GlobeNewswire) +6.12%
Feb-13-26 06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 07:30AM	Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma (GlobeNewswire)
02:33AM	Loading…
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks) -9.09%
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-19-25 07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-07-25 04:30PM	Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-12-25 05:40PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 (GlobeNewswire)
05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-11-25 08:44AM	Lyell acquires worldwide rights from ICT to CAR T-cell therapy (Pharmaceutical Technology)
Nov-10-25 07:30AM	Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer (GlobeNewswire)
Nov-03-25 09:00AM	Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-03-25 08:00AM	Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee (GlobeNewswire)
Sep-02-25 04:05PM	Lyell Immunopharma Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-12-25 06:17PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 (GlobeNewswire)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.26%
08:00AM	Loading…
Jul-25-25 08:00AM	Lyell Immunopharma Announces up to $100 Million Equity Private Placement (GlobeNewswire) +19.31%
Jun-23-25 05:00PM	Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +6.62%
Jun-18-25 07:12AM	Lyell reports new clinical data from trial of large B-cell lymphoma therapy (Clinical Trials Arena)
Jun-17-25 06:30AM	Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma (GlobeNewswire)
Jun-09-25 04:05PM	Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments (GlobeNewswire) -13.39%
Jun-04-25 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) +68.59% -14.92%
May-13-25 05:49PM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 (GlobeNewswire)
May-01-25 09:00AM	Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 (GlobeNewswire)
Apr-15-25 09:00AM	Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma (GlobeNewswire)
Mar-28-25 10:54AM	Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey) -8.83%
Mar-11-25 04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 (GlobeNewswire)
Feb-18-25 04:05PM	Lyell Immunopharma Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-22-25 12:00PM	Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-09-25 09:00AM	Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 09:35AM	After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) (Zacks)
Dec-30-24 09:35AM	After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) (Zacks)
Dec-13-24 09:35AM	Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround (Zacks) -11.37%
Dec-09-24 09:00PM	Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting (GlobeNewswire)
Nov-14-24 12:00PM	Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:22PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance) -17.57%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 (GlobeNewswire)
Nov-05-24 09:30AM	Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-24 04:00PM	Lyell Immunopharma Completes Acquisition of ImmPACT Bio (GlobeNewswire) +11.88% +16.63%
Oct-30-24 11:16AM	Lyell shares down as BofA double downgrades to Sell (Investing.com) -9.47%
Oct-25-24 11:56AM	Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline (Pharmaceutical Technology) -14.95%
Oct-24-24 04:00PM	Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies (GlobeNewswire) -5.22%
01:54PM	Lyell, in search of a turnaround, to buy cell therapy startup ImmPact (BioPharma Dive)
Oct-04-24 09:00AM	Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-24-24 04:05PM	Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day (GlobeNewswire) -7.53%
Aug-28-24 04:05PM	Lyell Immunopharma Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-07-24 05:41PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance) +6.38%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-06-24 08:00AM	3 Biotech Stocks to Sell in August Before They Crash & Burn (InvestorPlace)
Jun-26-24 02:44PM	Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial (Benzinga) -36.03%
07:00AM	Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology (GlobeNewswire)
Jun-03-24 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.68%
May-07-24 04:05PM	Lyell Immunopharma to Participate in BofA Securities Health Care Conference (GlobeNewswire)
May-06-24 10:53PM	LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024 (InvestorPlace) +7.63%
01:34PM	Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows (MT Newswires)
08:23AM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 (GlobeNewswire)
Mar-19-24 10:00AM	CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) (GlobeNewswire)
Mar-07-24 12:00PM	Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know (Zacks)
Mar-05-24 04:30PM	Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting (GlobeNewswire) +5.18%
Feb-28-24 04:44PM	Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights (GuruFocus.com)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Feb-26-24 04:05PM	Lyell Immunopharma Announces Participation in March Investor Conferences (GlobeNewswire) +9.62% +8.78%
Jan-03-24 04:05PM	Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.69%
Nov-09-23 04:05PM	Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma (GlobeNewswire) -6.81% -24.43%
Nov-07-23 04:33PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 (GlobeNewswire)
Oct-31-23 09:00AM	Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing (GlobeNewswire) -7.54%
Sep-27-23 09:00AM	Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-11-23 08:00AM	Cellares and Lyell to Evaluate Automated Manufacturing of Lyells CAR T-Cell Therapy on Cellares Cell Shuttle Platform (GlobeNewswire) +9.89%
Aug-31-23 04:05PM	Lyell Immunopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-23 07:10PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023 (GlobeNewswire)
Jul-12-23 08:47AM	Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-05-23 04:05PM	Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer (GlobeNewswire) -6.98%
Jun-16-23 10:47AM	Why Shares of Lyell Immunopharma Jumped This Week (Motley Fool) -17.36%
Jun-07-23 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.52%
Jun-01-23 07:55AM	Even after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down 31% over the past year (Simply Wall St.)
May-04-23 07:25PM	Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
06:25PM	Lyell Immunopharma: Q1 Earnings Snapshot (AP Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023 (GlobeNewswire)
May-02-23 04:05PM	Lyell Immunopharma to Participate in BofA Securities Healthcare Conference (GlobeNewswire) +12.08%
Apr-17-23 07:11AM	There's No Escaping Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) Muted Revenues (Simply Wall St.) +7.63%
Mar-27-23 04:52AM	Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains? (Zacks) +8.96%
Mar-26-23 10:14AM	Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Founder & Executive ChairmanDr. Richard D. Klausner M.D.

Ph.D.Dr. Lynn Seely M.D.

Chief Operating OfficerMr. Stephen J. Hill

Chief Scientific OfficerDr. Gary K. Lee Ph.D.

Founder & Scientific AdvisorProf. Stanley R. Riddell M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Seely Lynn	President and CEO	May 11 '26	Sale	18.91	388	7,337	73,878	Jun 15 06:37 PM
Lee Gary K.	Chief Scientific Officer	May 11 '26	Sale	18.92	130	2,460	17,808	Jun 15 06:35 PM
Hill Stephen J.	Chief Operating Officer	May 11 '26	Sale	18.92	89	1,684	17,894	Jun 15 06:34 PM
Bulis Veronica Sanchez	VP, Corporate Controller	May 11 '26	Sale	18.91	217	4,103	15,420	Jun 15 06:32 PM
Shook David	Chief Medical Officer	Jun 10 '26	Sale	12.64	1,977	24,989	20,923	Jun 11 04:07 PM
ARCH Venture Partners IX, LLC	10% Owner	Mar 06 '26	Buy	25.61	488,090	12,499,985	1,426,528	Mar 09 04:36 PM
ARCH Venture Fund XIII, L.P.	10% Owner	Mar 06 '26	Buy	25.61	488,090	12,499,985	1,426,528	Mar 09 04:34 PM
Seely Lynn	President and CEO	Feb 11 '26	Sale	23.39	7,455	174,372	74,266	Feb 12 08:47 PM
Hill Stephen J.	Chief Operating Officer	Feb 11 '26	Sale	23.39	1,236	28,910	17,795	Feb 12 08:46 PM
Lee Gary K.	Chief Scientific Officer	Feb 11 '26	Sale	23.39	1,671	39,085	16,938	Feb 12 08:44 PM
Hill Stephen J.	Chief Operating Officer	Feb 10 '26	Sale	23.12	109	2,520	19,031	Feb 11 09:05 PM
Lee Gary K.	Chief Scientific Officer	Feb 10 '26	Sale	23.12	147	3,399	18,609	Feb 11 09:04 PM
Seely Lynn	President and CEO	Feb 10 '26	Sale	23.12	438	10,127	81,721	Feb 11 09:03 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Feb 10 '26	Sale	23.12	254	5,872	15,637	Feb 11 09:00 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Dec 24 '25	Sale	38.67	1,136	43,929	8,077	Jan 06 04:02 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Dec 30 '25	Sale	32.32	936	30,252	7,141	Jan 06 04:02 PM
Seely Lynn	President and CEO	Nov 10 '25	Sale	16.11	412	6,637	67,159	Nov 12 08:36 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Nov 10 '25	Sale	16.10	239	3,848	9,213	Nov 12 08:34 PM
Lee Gary K.	Chief Scientific Officer	Nov 10 '25	Sale	16.16	138	2,230	15,366	Nov 12 08:33 PM
Hill Stephen J.	Chief Operating Officer	Nov 10 '25	Sale	16.12	95	1,531	15,750	Nov 12 08:31 PM
Seely Lynn	President and CEO	Aug 21 '25	Sale	10.54	7,257	76,518	67,571	Aug 22 04:07 PM
Hill Stephen J.	Chief Operating Officer	Aug 21 '25	Sale	10.54	1,004	10,586	15,845	Aug 22 04:06 PM
Newton Charles W.	Chief Financial Officer	Aug 21 '25	Sale	10.54	1,453	15,320	15,306	Aug 22 04:03 PM
Lee Gary K.	Chief Scientific Officer	Aug 21 '25	Sale	10.54	1,453	15,320	15,504	Aug 22 04:02 PM
Seely Lynn	President and CEO	Aug 12 '25	Sale	10.34	406	4,197	34,828	Aug 13 09:10 PM
Seely Lynn	President and CEO	Aug 11 '25	Sale	10.53	391	4,116	35,234	Aug 13 09:10 PM
Hill Stephen J.	Chief Operating Officer	Aug 12 '25	Sale	10.34	94	972	8,849	Aug 13 09:09 PM
Hill Stephen J.	Chief Operating Officer	Aug 11 '25	Sale	10.53	91	958	8,943	Aug 13 09:09 PM
Lee Gary K.	Chief Scientific Officer	Aug 12 '25	Sale	10.34	136	1,406	8,957	Aug 13 09:08 PM
Lee Gary K.	Chief Scientific Officer	Aug 11 '25	Sale	10.53	131	1,379	9,093	Aug 13 09:08 PM
Newton Charles W.	Chief Financial Officer	Aug 12 '25	Sale	10.34	136	1,406	8,759	Aug 13 09:06 PM
Newton Charles W.	Chief Financial Officer	Aug 11 '25	Sale	10.53	131	1,379	8,895	Aug 13 09:06 PM

Open in Screener

NKTX

Nkarta Inc

Jun 18 • 04:00PM ET

2.86

+0.22 8.33 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: FATE KROS MIST ALLO MDWD OBIO RNAC ALXO CLLS FHTX

| Held by: VTI IWM VXF IWN VTWO DFAS PRFZ IWC AVSC SFGV

Index	RUT	P/E	-	EPS (ttm)	-1.35	Insider Own	24.10%	Shs Outstand	71.29M	Perf Week	3.62%
Market Cap	204.62M	Forward P/E	-	EPS next Y	-1.37	Insider Trans	-0.18%	Shs Float	54.30M	Perf Month	6.72%
Enterprise Value	49.19M	PEG	-	EPS next Q	-0.36	Inst Own	62.05%	Short Float	9.63%	Perf Quarter	31.80%
Income	-99.93M	P/S	-	EPS this Y	-2.55%	Inst Trans	2.31%	Short Ratio	6.98	Perf Half Y	57.14%
Sales	0.00M	P/B	0.71	EPS next Y	5.46%	ROA	-23.72%	Short Interest	5.23M	Perf YTD	54.59%
Book/sh	4.01	P/C	0.89	EPS next 5Y	6.10%	ROE	-30.07%	52W High	3.65 -21.64%	Perf Year	57.14%
Cash/sh	3.22	P/FCF	-	EPS past 3/5Y	18.61% 23.69%	ROIC	-28.25%	52W Low	1.63 75.46%	Perf 3Y	-41.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.93% 8.18%	Perf 5Y	-89.20%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	10.70%	Oper. Margin	-	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.96	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.27	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.96	EPS Q/Q	13.38%	SMA20	0.88%	Beta	0.94	Target Price	11.33
Payout	-	Debt/Eq	0.26	Sales Q/Q	-	SMA50	-0.11%	Rel Volume	0.76	Prev Close	2.64
Employees	108	LT Debt/Eq	0.24	Earnings	May 12 AMC	SMA200	24.37%	Avg Volume	749.37K	Price	2.86
IPO	Jul 10, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.52% -	Trades		Volume	568,898	Change	8.33%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$14
Aug-14-24	Upgrade	Raymond James	Outperform → Strong Buy	$16
Mar-22-24	Downgrade	Raymond James	Strong Buy → Outperform	$13 → $16
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Oct-10-22	Initiated	Canaccord Genuity	Buy	$25
Jul-28-22	Initiated	Needham	Buy	$26
Jul-18-22	Initiated	SVB Leerink	Outperform	$30
Mar-11-22	Initiated	Raymond James	Outperform	$17
Mar-08-22	Initiated	H.C. Wainwright	Buy	$25
Jan-06-22	Initiated	William Blair	Outperform
Nov-18-21	Initiated	SMBC Nikko	Outperform	$50
Jul-16-21	Initiated	Oppenheimer	Outperform	$75
Aug-04-20	Initiated	Stifel	Buy	$41
Aug-04-20	Initiated	Mizuho	Buy	$34
Aug-04-20	Initiated	Evercore ISI	Outperform	$55
Aug-04-20	Initiated	Cowen	Outperform

Show Previous Ratings

May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire)
May-19-26 09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire)
May-12-26 04:01PM	Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) -6.71%
Apr-15-26 04:01PM	Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers (GlobeNewswire) +5.68% +15.70%
Apr-09-26 07:00AM	Nkarta to Participate in Needham Virtual Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Mar-25-26 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-27-26 08:00AM	Nkarta to Participate in March Investor Conferences (GlobeNewswire)
Dec-02-25 07:09AM	Nkarta to Participate in Evercore Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-30-25 01:14PM	Nkarta to Participate in November Investor Conferences (GlobeNewswire)
Oct-22-25 10:07AM	Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting (GlobeNewswire) -7.95%
Sep-02-25 08:01AM	Nkarta to Participate in a September Investor Conference (GlobeNewswire)
Aug-12-25 04:01PM	Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +12.76%
Jul-23-25 08:01AM	Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +7.21%
Jun-06-25 08:52AM	Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus (GlobeNewswire)
12:00PM	Loading…
May-19-25 12:00PM	Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
May-15-25 03:46PM	Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space (Benzinga) -8.02%
May-14-25 04:01PM	Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-14-25 12:00PM	Nkarta (NKTX) Upgraded to Buy: Here's Why (Zacks) +7.94%
Apr-01-25 08:01AM	Nkarta to Participate in an April Investor Conference (GlobeNewswire)
Mar-31-25 10:41AM	Nkarta: Grinding Lower, Trying To Find Support (Seeking Alpha) -8.00%
10:15AM	Nkarta: Betting On The Turnaround (Seeking Alpha)
Mar-27-25 06:55AM	Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy (BioPharma Dive) +43.80%
Mar-26-25 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-20-25 09:35AM	Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-19-25 09:35AM	Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-25-25 08:01AM	Nkarta to Participate in March Investor Conferences (GlobeNewswire)
Dec-05-24 06:01AM	Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 (GlobeNewswire)
Nov-26-24 07:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire)
Nov-22-24 06:50AM	Nkarta price target lowered to $16 from $20 at Mizuho (TipRanks)
08:02AM	Loading…
Nov-12-24 08:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire) -10.03%
Nov-07-24 04:02PM	Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-09-24 08:00AM	Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month (Benzinga)
Sep-03-24 04:01PM	Nkarta to Participate in Upcoming Investor Conference (GlobeNewswire)
Aug-14-24 12:37PM	Why Nkarta Stock Is Soaring Today (Motley Fool)
Aug-13-24 09:03PM	Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-24-24 06:00AM	Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus (GlobeNewswire)
Jul-16-24 06:01AM	Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President (GlobeNewswire) +13.96%
Jul-10-24 12:00PM	Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know (Zacks)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-27-24 06:00AM	Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications (GlobeNewswire)
Jun-13-24 04:01PM	Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors (GlobeNewswire)
May-10-24 02:56PM	Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis (GuruFocus.com)
May-09-24 10:57PM	NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-07-24 06:30AM	Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar (InvestorPlace)
Apr-03-24 04:02PM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-24 04:06PM	Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday (Investor's Business Daily) +17.60% -5.91%
06:30AM	Nkarta Announces Pricing of $240 Million Underwritten Offering (GlobeNewswire)
Mar-23-24 05:31AM	Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment (GuruFocus.com)
Mar-22-24 04:03PM	Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line (Investor's Business Daily) -31.28% +17.60%
09:18AM	Nkarta's blood cancer CAR stalls again, with falling response rate forcing it out of the race (FierceBiotech.com)
Mar-21-24 10:54PM	NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-19-24 07:29AM	3 Overlooked Stocks Ready to Capture the Market by Storm (InvestorPlace) +7.19%
Feb-29-24 06:30AM	3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket (InvestorPlace) +11.13%
Feb-28-24 08:01AM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:19PM	Last Call! 7 Small-Cap Stocks Ready to Explode in Value (InvestorPlace) -7.66%
Feb-08-24 09:32AM	3 Under-the-Radar Stocks Set to Soar 300% by 2026 (InvestorPlace) +7.87%
Feb-06-24 12:50PM	3 Sleeper Stocks With Serious Potential to Make You a Millionaire (InvestorPlace) +11.95%
Feb-05-24 12:41PM	3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential (InvestorPlace) -5.59%
Feb-04-24 08:00AM	Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge (InvestorPlace)
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire)
Dec-09-23 08:31PM	Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition (GlobeNewswire)
Dec-08-23 12:00PM	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy (Zacks)
Nov-14-23 03:56PM	T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta Inc (GuruFocus.com) +20.42%
Nov-09-23 04:02PM	Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga)
Nov-07-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 02:06PM	Want To Invest In Penny Stocks? Here Are Three That Analysts Think Could Deliver Over 300% Returns (Benzinga)
Oct-18-23 10:47AM	Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug (Zacks)
01:18AM	'The world increasingly needs Arm,' says KeyBanc: 4 big analyst picks (Investing.com)
Oct-17-23 08:17PM	Nkarta stock soars 112% after FDA clears cell therapy to go beyond cancer into lupus (FierceBiotech.com) +112.16%
11:47AM	Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis (PR Newswire)
07:01AM	Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis (GlobeNewswire)
Oct-16-23 04:01PM	Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures (GlobeNewswire)
Oct-02-23 03:07PM	3 Promising Biotech Stocks That Will Make Early Investors Rich (InvestorPlace) -5.76%
Aug-10-23 07:01AM	Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-03-23 08:02AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire)
Jul-31-23 06:30PM	3 Hidden Penny Stocks That Could Turn $100 into $10,000 (InvestorPlace) +6.51%
Jul-05-23 04:02PM	Nkarta Appoints Alyssa Levin Chief Financial and Business Officer (GlobeNewswire) -6.87%
Jun-28-23 09:35AM	Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks (Zacks) -11.74%
Jun-27-23 01:02PM	Why Shares of Nkarta Are Slumping Tuesday (Motley Fool) -37.97%
07:01AM	Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Jun-26-23 04:01PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +12.24%
Jun-10-23 10:47AM	Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-11-23 04:02PM	Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-09-23 07:15AM	We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely (Simply Wall St.)
May-07-23 12:50PM	7 Stocks With Promising Upside Potential for 100% Returns (InvestorPlace)
Apr-17-23 05:01PM	Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 09:06PM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire) +14.06%
Apr-11-23 09:46AM	3 Biotech Stocks to Watch for Potential Breakthroughs (InvestorPlace)
Mar-30-23 04:01PM	Nkarta Announces Departure of Chief Financial & Business Officer (GlobeNewswire)
Mar-16-23 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-17-23 05:35AM	Nkarta, Inc. (NASDAQ:NKTX) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Feb-09-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Jan-09-23 04:30PM	Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer (GlobeNewswire) -7.77%

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

CEO & DirectorMr. Paul J. Hastings

President and Principal Accounting & Financial OfficerDr. Nadir Mahmood Ph.D.

Ph.D.Dr. Shawn Rose M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HASTINGS PAUL J	Chief Executive Officer	Jan 15 '26	Sale	2.07	26,046	53,915	390,023	Jan 20 05:39 PM
Mahmood Nadir	President	Jan 15 '26	Sale	2.07	5,649	11,693	167,727	Jan 20 05:38 PM

LYEL

Lyell Immunopharma Inc

NKTX

Nkarta Inc

Upgrade your Finviz experience